Logo

GTBP

GT Biopharma, Inc.

GTBP

GT Biopharma, Inc. • NASDAQ
$0.79 ▼ -1.46% (-0.01)
Market Cap $8.39 M
52w High $4.10
52w Low $0.54
Dividend Yield 0%
P/E -0.23
Volume 175.42K
Outstanding Shares 10.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.382M ▲ $-3.114M ▼ 0% $-0.83 ▼ $-3.114M ▼
Q2-2025 $0 $1.513M ▼ $-1.433M ▼ 0% $-0.55 ▼ $-1.433M ▼
Q1-2025 $0 $1.932M ▼ $-776K ▲ 0% $-0.33 ▲ $-775.999K ▲
Q4-2024 $0 $3.763M ▲ $-3.775M ▼ 0% $-1.99 ▼ $-3.775M ▼
Q3-2024 $0 $3.604M $-3.411M 0% $-1.53 $-3.411M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.621M ▼ $4.321M ▼ $1.321M ▼ $3M ▼
Q2-2025 $5.228M ▲ $7.124M ▲ $2.307M ▼ $4.817M ▲
Q1-2025 $2.365M ▼ $2.658M ▼ $3.638M ▼ $-980K ▲
Q4-2024 $3.951M ▼ $4.232M ▼ $5.902M ▲ $-1.67M ▼
Q3-2024 $6.418M $6.759M $4.662M $2.097M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.114M ▼ $-3.677M ▼ $0 $977K ▼ $-2.7M ▼ $-3.677M ▼
Q2-2025 $-1.433M ▼ $-3.014M ▼ $0 $5.877M ▲ $2.863M ▲ $-3.014M ▼
Q1-2025 $-776K ▲ $-2.202M ▲ $0 ▼ $616K ▲ $-1.586M ▲ $-2.202M ▲
Q4-2024 $-3.775M ▼ $-2.468M ▲ $1K ▲ $0 $-2.467M ▲ $-2.468M ▲
Q3-2024 $-3.411M $-2.737M $-1K $0 $-2.738M $-2.737M

Five-Year Company Overview

Income Statement

Income Statement GT Biopharma is still a pure research-stage biotech company with essentially no product revenue. Its income statement is driven almost entirely by research and corporate expenses, which lead to recurring losses each year. These losses have been relatively small in absolute dollar terms but persistent over time. Earnings per share look very weak, but that is heavily distorted by multiple reverse stock splits, which shrink the share count and make past losses look larger on a per‑share basis. The core message: this is an early-stage company still in the spending phase, with no commercial income yet and a clear dependence on future milestones (like partnerships, licensing deals, or eventual drug approvals) to change that picture.

Balance Sheet

Balance Sheet The balance sheet is very lean, with a small base of total assets and only modest cash on hand. There is little or no traditional financial debt in recent years, which reduces interest burden but also suggests that funding has likely come mostly from issuing equity rather than borrowing. Shareholders’ equity has hovered around break-even over time and was even negative in the past, which is common for small biotechs that fund long R&D programs with repeated capital raises. Overall, the balance sheet shows a company with limited financial cushion and strong dependence on ongoing access to external financing to support its pipeline.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the cost of running clinical and preclinical programs without any product revenue coming in. Free cash flow is also negative, but the company does not appear to spend much on physical assets, so nearly all cash usage is tied to people, trials, and R&D activities. In practical terms, this means GT Biopharma burns cash at a steady pace and must periodically raise new money to continue operations. The company’s future cash position will largely depend on its ability to secure equity offerings, grants, partnerships, or upfront payments from larger pharmaceutical companies.

Competitive Edge

Competitive Edge GT Biopharma sits in a very crowded and fast-moving immuno-oncology space but is trying to differentiate itself with its TriKE platform, which harnesses the body’s natural killer cells in an “off-the-shelf” way. The built-in immune stimulant (IL‑15) and the use of camelid nanobodies in its newer versions are important technical twists that may provide potency and safety advantages versus some competing approaches. On the other hand, GT Biopharma is a small player facing much larger, better-funded competitors in cancer immunotherapy. Its competitive strength will depend on whether clinical data confirm the early safety and activity signals and whether it can convert its technology into strong partnerships or co-development deals. Until then, its competitive position remains promising in theory but unproven in the marketplace.

Innovation and R&D

Innovation and R&D Innovation is the core of GT Biopharma’s story. The TriKE platform is versatile, designed to redirect natural killer cells against different targets, and is protected by patents that extend well into the next decade. The move to second‑generation TriKEs using nanobodies is a meaningful upgrade aimed at higher potency, better tissue penetration, and easier manufacturing. The pipeline spans blood cancers, solid tumors, and even potential autoimmune indications, showing that management sees this as a broad platform rather than a single‑product bet. However, most programs are still in early clinical or preclinical stages, so there is substantial scientific, regulatory, and execution risk ahead, and timelines are likely to be long before any commercial product emerges, if at all.

Summary

Overall, GT Biopharma looks like a classic early-stage biotech: science-rich, revenue-poor, and financially dependent on external funding. The company has no commercial sales, a thin balance sheet, ongoing cash burn, and a history of reverse splits that point to repeated equity-driven financing. On the positive side, it has a clearly defined technological focus, a differentiated natural-killer-cell engager platform, and patent protection that could support a real franchise if clinical results are compelling. The key swing factors going forward will be: the quality and consistency of trial data, the company’s ability to secure partnerships or non-dilutive funding, and its capacity to manage cash while advancing multiple programs. The upside potential is tightly linked to scientific and clinical success, while the primary risks center on trial outcomes, funding access, and competition from better-capitalized immuno-oncology players.

NEWS

November 19, 2025 · 8:00 AM UTC

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Read more

November 14, 2025 · 9:00 AM UTC

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more